Final program - Societa' Italiana di Cancerologia
←
→
Trascrizione del contenuto della pagina
Se il tuo browser non visualizza correttamente la pagina, ti preghiamo di leggere il contenuto della pagina quaggiù
Final program
UNDER THE AUSPICE OF
della Fondazione per esteso
SUPPORTED BY
FAMIGLIA DI
ELENA
CAPPANNINI
FONDAZIONE AIRC PER LA RICERCA SUL CANCRO
Comitati
SCIENTIFIC COORDINATOR
Nicola Normanno (National Cancer Institute “G. Pascale”, Naples)
LOCAL SCIENTIFIC AND ORGANIZING COMMITTEE
Gerardo Botti (National Cancer Institute “G. Pascale”, Naples)
Lucia Altucci (University of Campania “Luigi Vanvitelli”, Naples)
Roberto Bianco (University “Federico II”, Naples)
Alfredo Budillon (National Cancer Institute “G. Pascale”, Naples)
Luigi Buonaguro (National Cancer Institute “G. Pascale”, Naples)
Fortunato Ciardiello (University of Campania “Luigi Vanvitelli”, Naples)
Vittorio Colantuoni (University of Sannio, Benevento)
Daniela Corda (Institute of Protein Biochemistry - National Research Council (CNR), Naples)
Rosamarina Melillo (University “Federico II”, Naples)
Francesco Perrone (National Cancer Institute “G. Pascale”, Naples)
Stefania Scala (National Cancer Institute “G. Pascale”, Naples)
SIC SCIENTIFIC BOARD
President
Gabriella Sozzi (IRCCS National Cancer Institute, Milan, Italy)
President Elect
Nicola Normanno (National Cancer Institute “G. Pascale”, Naples, Italy)
Board
Paola Chiarugi (University of Florence, Italy)
Amedeo Columbano (University of Cagliari, Italy)
Rita Falcioni (Regina Elena National Cancer Institute, Rome, Italy)
Davide Melisi (University of Verona, Italy)
Katia Scotlandi (IRCCS Orthopaedic Rizzoli Institute, Bologna, Italy)
Elda Tagliabue (IRCCS National Cancer Institute, Milan, Italy)
Giulia Taraboletti (“Mario Negri” Institute for Pharmacological Research, Bergamo, Italy)
Members under 35
Antonino Bruno (MultiMedica, Milan)
Marco Macagno (University of Turin)
Past President
Silvia Giordano (University of Turin) SIC Secretariat
Società Italiana di Cancerologia
Via G. Venezian, 1 - 20133 Milano MI
E-mail: sic@istitutotumori.mi.it
www.cancerologia.it
Organizing Secretariat
Via Sassonia, 30 - 47922 Rimini RN
E-mail: sic2019@adriacongrex.it
www.adriacongrex.it
1Faculty
Lucia Altucci Campania University “Luigi Vanvitelli”, Naples, Italy
Guillem Argilés Vall d’Hebrón University Hospital, Barcelona, Spain
Ludovic Barault Candiolo Cancer Institute, FPO-IRCCS, Candiolo TO, Italy
Fabrizio Bianchi IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo FG, Italy
Roberto Bianco University “Federico II”, Naples, Italy
Antonino Bruno Multimedica, Milan, Italy
Alfredo Budillon National Cancer Institute “G. Pascale”, Naples, Italy
Federico Caligaris Cappio President Associazione Italiana per la Ricerca sul Cancro, Milan, Italy
Michele Ceccarelli Sannio University, Benevento, Italy
Paola Chiarugi University of Florence, Italy
Vittorio Colantuoni University of Sannio, Benevento, Italy
Amedeo Columbano University of Cagliari, Italy
Daniela Corda Institute of Protein Biochemistry - National Research Council (CNR), Naples, Italy
Elisabetta Dejana University of Milan IFOM, Milan, Italy
Federica Di Nicolantonio University of Turin, Italy
Riccardo Dolcetti The University of Queensland Diamantina Institute, Brisbane, Australia
Manel Esteller Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain
Rita Falcioni Regina Elena National Cancer Institute, Rome, Italy
Christian Frezza University of Cambridge, United Kingdom
Silvia Giordano University of Turin, Italy
Elena Jachetti IRCCS National Cancer Institute, Milan, Italy
Marco Macagno University of Turin, Italy
Sara Mainardi The Netherlands Cancer Institute, Amsterdam, The Netherlands
Ilaria Malanchi The Francis Crick Institute, London, UK
Erika Martinelli Campania University “Luigi Vanvitelli”, Naples, Italy
Rosamarina Melillo University “Federico II”, Naples, Italy
Davide Melisi University of Verona, Italy
Saverio Minucci University of Milan, Italy
Clara Montagut MIM Hospital del Mar Medical Research Institute, Barcelona, Spain
Nicola Normanno National Cancer Institute “G. Pascale”, Naples, Italy
Gabriele Picco Wellcome Sanger Institute Hinxton, Cambridge, United Kingdom
Maria Rescigno Humanitas University, Milan, Italy
Antoni Ribas University of California, Los Angeles, USA
Licia Rivoltini IRCCS National Cancer Institute, Milan, Italy
Stefania Scala National Cancer Institute “G. Pascale”, Naples, Italy
Katia Scotlandi IRCCS Orthopaedic Rizzoli Institute, Bologna, Italy
Gabriella Sozzi IRCCS National Cancer Institute, Milan, Italy
Elda Tagliabue IRCCS National Cancer Institute, Milan, Italy
Giulia Taraboletti “Mario Negri” Institute for Pharmacological Research, Bergamo, Italy
Jean Claude Zenklusen National Cancer Institute, Bethesda, USA
2Program at a Glance
Wednesday, 6 Thursday, 7 November 2019 Friday, 8 November 2019
November 2019
Plenary Room Plenary Room Partenope Room Plenary Room Partenope Room
Lecture
8.30-8.50
Epigenetics and non Immunotherapy:
coding RNAs: from from the rationale to
basic science to clinic applications
clinical applications 08.50-10.00
08.30-10.00
Coffee Break
10.00-10.15 Coffee Break
10.00-10.30
SIC meets
Pharma Industry
10.15-12.00
Poster discussion 2A Poster discussion 2B
10.30-12.00 10.30-12.00
Registration
12.00
Poster discussion 1A Poster discussion 1B
12.00-13.30 12.00-13.30
Poster viewing
Opening Address with authors
13.00 - 14.00 (Mirabilis Room)
Lunch 12.00-13.00
13.30 - 14.30
Opening Lecture Poster viewing Lunch
14.00 -15.00 with authors 13.00 - 14.00
(Mirabilis Room)
Coffee Break 14.30-15.30
15.00 - 15.30 Tumor progression,
microenvironment
Tumor cell metabolism and metastases
15.30-17.00 14.00-15.30
Precision medicine:
biomarkers driven
oncology Coffee Break
15.30 -17.00 17.00-17.15 Closing Lecture
15.30 - 16.15
SIC/ESMO/EACR -
Award Ceremony Young investigators Award Ceremony
17.00 -17.30 17.15 - 18.30 16.15 - 16.45
Mechanisms of “Giorgio Prodi”
resistance to anti- Lecture
cancer therapy
17.30 -19.00 18.30 - 19.15
SIC General Assembly
19.15 - 19.45
Congress Event
Get together cocktail
3Wednesday, November 6th
12.00 Registration
13.00 - 14.00 Opening Address
14.00-15.00 Opening Lecture Plenary Room
The Cancer Genome Atlas and beyond: Taking genomics to the clinic
Jean Claude Zenklusen, Bethesda (USA)
15.00-15.30 Coffee break
15.30-17.00 Precision medicine: biomarkers driven oncology Plenary Room
Chairs: Rita Falcioni, Rome (Italy) - Elda Tagliabue, Milan (Italy)
Large scale systems biology and bioinformatics in cancer genomics
Michele Ceccarelli, Benevento (Italy)
R1 An integrated multi-omic approach for prognostically relevant subtypes classification of ovarian cancer
patients
D. Mezzanzanica (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy),
S. Pignata, D. Califano, S. Canevari, S. Losito, G. Baldassarre, F. Perrone, M. Bagnoli, L. De Cecco
Potential Clinical Utility of analysing circulating tumor DNA for CRC
Clara Montagut, Barcelona (Spain)
N1 Pharmacological inhibition of the ALK/MET axis elicits therapeutic potential in consensus molecular
subtype 1 colon cancer patients
M. Mazzeschi (University of Bologna, Italy), M. Sgarzi, A. Romanzi, V. Gelfo, M. Cardi, S. Santi, M. Fiorentino,
A. Ardizzoni, B. Gyorffy, Y. Yarden, G. D’ Uva, M. Lauriola
17.00-17.30 Award Ceremony Plenary Room
“Elena Cappannini” award for the best 2018 publication
“Pezcoller Foudation-SIC - Patrizia Coser” Fellowship 2020-2021
17.30-19.00 Mechanisms of resistance to anti-cancer therapy Plenary Room
Chairs: Silvia Giordano, Turin (Italy) - Davide Melisi, Verona (Italy)
Prioritisation of cancer therapeutic targets using CRISPR (Clustered Regularly Interspaced Short Palindromic
Repeats)-Cas9 screens
Gabriele Picco, Cambridge (UK)
I1 PAK1 as a novel mediator of resistance to endocrine therapy and CDK4/6 inhibitors in ER+/PAK1 amplified
breast cancer
S. Belli (University of Naples “Federico II”, Naples, Italy) C. Di Mauro, D. Esposito, A. Pesapane, F. Napolitano,
A. Santaniello, P. De Placido, P. Cascetta, A. Carratù, E. Mozzillo, R. Marciano, A. Servetto, R. Bianco, L. Formisano
The RAS paradigm revisited: implications for targeted therapy resistance and the identification of
effective drug combinations for RAS mutant tumors
Sara Mainardi, Amsterdam (NL)
H2 Combined treatment with parp and CHK1 inhibitors: a new strategy for the treatment of the MYCN-
amplified neuroblastoma
S. Di Giulio (University of Rome “La Sapienza”, Rome, Italy, M. Petroni, V. Colicchia, F. Pedretti, F. Pastorino, F. Fabretti,
V. Nicolis Di Robilant, R. Cepollaro, F. Belardinilli, G. Scafetta, G. Peruzzi, V. Ramponi, P. Infante, M. Moretti, A. Coppa,
A. Bartolazzi, M. Ponzoni, G. Giannini
4Thursday, November 7th
8.30-10.00 Epigenetics and non coding RNAs (RiboNucleic Acid):
from basic science to clinical applications Plenary Room
Chairs: Katia Scotlandi, Bologna (Italy) - Gabriella Sozzi, Milan (Italy)
Epigenome deregulation in cancer: drug discovery approaches for prevention and treatment
Lucia Altucci, Naples (Italy)
H1 MiR-302b-mediated BRCAness improves sensitivity to PARP inhibitors in BRCA-1 not-mutated TNBC
A. Cataldo (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy)
I. Plantamura, S. Romero-Cordoba, G. Cosentino, M.V. Iorio
Cancer Epigenetics: From Knowledge to Applications
Manel Esteller, Barcelona (Spain)
F1 MiR-214 in tumor-stroma cell interactions
F. Orso, F. Virga, D. Dettori, M. Paradzik, D. Baruffaldi, A. Massa, M. Van Wynendaele, E. Bolli, F. Cavallo, M. Forni,
L. Salmena, M. Mazzone, P.P. Pandolfi, D. Taverna (University of Torino and MBC, Turin, Italy)
10.00-10.15 Coffee break
10.15-12.00 SIC meets Pharma Industry Not accredited CME Session Plenary Room
The Future of Precision Medicine: a Roche perspective
Roberto Scalamogna, Monza (Italy)
From myeloid cell differentiation marker to therapeutic target in acute myeloid leukemia: the long journey
of CD157
Enza Ferrero, Turin (Italy) - Yuliya Yakymiv, Turin (Italy)
TruSight Oncology 500, a comprehensive assay for genomic profiling and beyond
Gina De Bonis, Milan (Italy)
AstraZeneca Oncology Commitment to Lung Cancer
Giovanni Melillo, Milan (Italy)
5Thursday, November 7th
12.00-13.30 Poster Discussion 1A
PRECISION MEDICINE Plenary Room
Chairs: Federica Di Nicolantonio, Turin (Italy) - Erika Martinelli, Naples (Italy)
A4 Development and exploitation of a mouse model of intrahepatic cholangiocarcinoma driven by oncogenic
FGFR2 fusions
G. Cristinziano (IRCCS Regina Elena National Cancer Institute, Rome, Italy), M. Porru, D. Lamberti, C.A. Amoreo, S.
Buglioni, M.G. Diodoro, M.J. Borad, C. Leonetti, S. Anastasi, O. Segatto
E7 Fatty acid uptake as novel actionable target of HER2-positive breast cancer stem cells resistant to targeted
therapy
L. Castagnoli, C. Vernieri, E. Fasano, A. Belfiore, S. Faraci, P. Corsetto, A. Rizzo, A. Vingiani, M. Di Nicola, M. Dugo, G.
Pruneri, E. Tagliabue, S. Pupa (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy)
I5 Tumor-stroma interactions mediated by Semaphorin 6A as a determinant of drug resistance in BRAF-Mut
melanoma
R. Loria (IRCCS Regina Elena National Cancer Institute, Rome, Italy), I. Falcone, M. Di Martile, V. Caprara, R. Fraioli, V.
Laquintana, L. Rosanò, D. Del Bufalo, L. Ciuffreda, M. Milella, R. Falcioni
K36 A novel mechanism of induction of anticancer adaptive immunity elicited by BoxA, a fragment of HMGB1
G. D’Agostino (Universita’ degli studi del Sannio, Benevento, Italy)
L3 p27kip1 regulates haematopoiesis by inducing notch signaling pathway
I. Segatto, G.L. Rampioni Vinciguerra, F. Citron, D. Viotto, A. Vecchione, B. Belletti,
G. Baldassarre (Centro di Riferimento Oncologico di Aviano (CRO), Aviano, Italy)
N4 Dynamics of RAS/BRAF mutations in cfDNA from metastatic colorectal carcinoma patients enrolled in the
ermes clinical trial
A.M. Rachiglio (Istituto Nazionale Tumori “Fondazione G. Pascale” - IRCCS Naples, Italy), L. Forgione, R. Pasquale, C.
Roma, E. Maiello, F. Di Costanzo, A. Cassata, E. Tamburini, G. Tonini, R. Bordonaro, G. Rosati, A. Zaniboni, S. Lonardi,
D. Ferrari, G.L. Frassineti, S. Tamberi, S. Pisconti, F. Di Fabio, C. Pinto, N. Normanno
O4 Circulating tumor DNA as a follow-up monitoring tool in triple negative breast cancer patients
Ortolan E. (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy), V. Appierto, S. Di Cosimo, S. Veneroni, C. De
Marco, E. Cavadini, G. Pruneri, G. Bianchi, M.G. Daidone
P8 Plasmatic CXCL8 is a marker for TGFß-activated kinase 1 (TAK1) activation which may predict resistance
to nanoliposomal irinotecan (nal-IRI) in gemcitabine-refractory pancreatic cancer (PC) patients
R. Santoro (University of Verona, Italy), V. Merz, C. Zecchetto, F. Simionato, G. Piro, F. Sabbadini, A. Cavaliere, S.
Casalino, A. Auriemma, D. Melisi
6Thursday, November 7th
12.00-13.30 Poster Discussion 1B
TUMOR IMMUNOLOGY AND MICROENVIRONMENT Partenope Room
Chairs: Daniela Corda, Naples (Italy) - Rosa Marina Melillo, Naples (Italy)
C1 High somatic mutation and neoantigen burden do not correlate with decreased progression-free survival in
HCC patients not undergoing immunotherapy
A. Mauriello, R. Zeuli, B. Cavalluzzo, A.C. Petrizzo, M.L. Tornesello, F.M. Buonaguro, M. Ceccarelli, M. Tagliamonte
(Istituto Nazionale Tumori “Pascale”, Naples, Italy), L. Buonaguro
O1 Multiparametric immune profiling to predict the risk of cancer development in solid organ transplant
patients
M. Cangemi (Centro di Riferimento Oncologico di Aviano, Italy), E. Rampazzo, S. Zanussi, D. Martorelli, R.M. Tedeschi,
A. De Rossi, A. Steffan, R. Dolcetti, E. Vaccher E.
T2 Modulation of the pulmonary microbiota as a new approach to treat and prevent cancer and metastasis of
various histotypes in the lung
V.M. Le Noci (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy), S. Guglielmetti, S. Arioli, M. Sommariva, F.
Bianchi, T. Triulzi, A. Balsari, E. Tagliabue, L. Sfondrini
T4 Secretion of the pro-inflammatory cytokine IFNg produced by activated NK and GD2 redirected CAR-T
cells overcomes MycN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape
M. Caforio (Bambino Gesù Children’s Hospital, Rome, Italy), C. Sorino, I. Caruana, G. Weber, A. Camera, L. Cifaldi, B.
De Angelis, A. Vitale, B.M. Goffredo, M. Compagnone, D. Fruci, C. Quintarelli, M. Fanciulli, F. Locatelli, V. Folgiero
T6 An intrinsic PD-1 circuit sustains proliferation and motility of thyroid cancer cells through a SHP2/Ras/Raf/
Erk signaling cascade
F. Liotti (University of Naples “Federico II”, Naples, Italy), N. Kumar, N. Prevete, M. Marotta, S. Moretti, S. Paladino, C.
Ierano, P. Rea, R. Franco, S. Scala , E. Puxeddu, R. M. Melillo
T16 Preclinical validation of mesothelin as a new immunotherapeutic target for aggressive colorectal cancer
E. Torchiaro (Candiolo Cancer Institute, Candiolo, Italy), M. Cortese, C. Petti, V. Leuci, R. Rotolo, D. Sangiolo, E. Medico
T21 Immunogenic tumor cell lysates modulate coding and non-coding RNA profiles of dendritic cell vaccine
based on immunogenic cell death
J. Dal Col (Univerity of the study of Salerno, Italy), M. Ravo, B. Montico, G. Giurato, D. Memoli, R. Tarallo, A. Nigro, L.
Ricciardi, A. Weisz, A. Steffan, R. Dolcetti, C. Stellato, D.A. Faè, V. Casolaro
U4 Tumor Associated Macrophages: Toward A Better Understanding Of Their Cancer Driver Capability In
Malignant Pleural Mesothelioma
E. Digifico (Humanitas University Pieve Emanuele, Italy), M. Erreni, G.L. Ceresoli, M. Roncalli, R. Frapolli, M. D’ Incalci,
C. Belgiovine, P. Allavena
13.30-14.30 Lunch
14.30-15.30 Poster viewing with authors Mirabilis Room
7Thursday, November 7th
15.30-17.00 Tumor cell metabolism Plenary Room
Chairs: Paola Chiarugi, Florence (Italy) - Amedeo Columbano, Cagliari (Italy)
The role of mitochondria in cancer
Christian Frezza, Cambridge (UK)
G2 Targeting of glutamine synthetase skews macrophages towards a M1-like phenotype and inhibits tumor
metastasis
A. Castegna (University of Bari, Italy), A. Menga, M. Mazzone
Tackling metabolic plasticity of tumor cells
Saverio Minucci, Milan (Italy)
G1 Reprogramming of amino acid transporters induces aspartate and glutamate dependency and drives
endocrine resistance in breast cancer
M. Bacci, N. Lorito, L. Ippolito, M. Ramazzotti, S. Luti, S. Romagnoli, M. Parri, F. Bianchini, F. Cappellesso, F. Virga,
Q. Gao, B.M. Simões, E. Marangoni, L.A. Martin, G. Comito, M. Ferracin, E. Giannoni, M. Mazzone, P. Chiarugi,
A. Morandi (University of Florence, Italy)
17.00-17.15 Coffee break
17.15-18.30 SIC (Società Italiana Cancerologia) Plenary Room
ESMO (European Society for Medical Oncology)
EACR (European Association for Cancer Research)
Young investigators
Chairs: Antonino Bruno, Milan (Italy) - Marco Macagno, Turin (Italy)
Stromal accomplices drive neuroendocrine features and immune escape in prostate cancer
Elena Jachetti, Milan (Italy)
Finding a career path for a medical oncologist in current European panorama
Guillem Argilés, Barcelona (Spain)
From convincing yourself to convincing others
Ludovic Barault, Candiolo Turin (Italy)
18.30-19.15 “Giorgio Prodi” Lecture Plenary Room
Infection-driven tumors: a career lesson for cancer immunotherapy
Riccardo Dolcetti, Brisbane (Australia)
19.15-19.45 SIC General Assembly
8Friday, November 8th
Plenary Room
8.30-8.50 The HEPAMUT project:
a road to personalized therapeutic cancer vaccine for liver cancer *Not accredited CME Lecture
Luigi Buonaguro, Naples, Italy
8.50-10.00 Immunotherapy: from the rationale to clinic applications Plenary Room
Chairs: Federico Caligaris Cappio, Milan (Italy) - Nicola Normanno, Naples (Italy)
Myeloid cells as biomarker and immunomodulating target in cancer
Licia Rivoltini (Milan, Italy)
A - Marchio con nome della Fondazione per esteso
T1 NK cells specifically TCR-dressed to kill cancer cells Versione su una riga
N. Mensali (Oslo University Hospital, Norway) P. Dillard, M. Hebeisen, S. Lorenz, T. Theodossiou, M. Myhre, A. Fåne,
G. Gaudernack, G. Kvalheim, J. Myklebust, E. Inderberg, S. Wälchli
Response and resistance to PD-1 blockade therapy supported by
Antoni Ribas, Los Angeles (USA)
10.00-10.30 Coffee break
10.30-13.00 Poster Discussion 2A
CANCER GENETICS, EPIGENETICS AND TUMOR PROGRESSION Plenary Room
Chairs: Fabrizio Bianchi, San Giovanni Rotondo (Italy) - Vittorio Colantuoni, Benevento (Italy) FONDAZIONE AIRC PER LA RICERCA SUL CANCRO
B2 Exploring the transcriptional landscape of MBCs characterized for germline mutations in homologous
recombination genes by RNA-sequencing
V. Zelli (Sapienza University of Rome, Italy), V. Silvestri, V. Valentini, A. Bucalo, P. Rizzolo, I. Zanna, L. Cortesi, D. Calistri,
M.G. Tibiletti, G. Giannini, S.B. Fox, D. Palli, L. Ottini
C4 The transcriptional landscape of an aggressive lung adenocarcinoma molecular subtype
V. Melocchi (Fondazione IRCCS - Casa Sollievo della Sofferenza, Unit of Oncology Biomarkers, San Giovanni Rotondo -
FG, Italy), F. Mazzarelli, E. Dama, T. Colangelo, R. Cuttano, F. Bianchi
C11 Molecular olecular characterization of estrogen recptor β actions in triple negative breast cancer
G. Pecoraro (University of Salerno, Italy), E. Alexandrova, P. Saggese, J. Lamberti, G. Giurato, M. Ravo, F. Collina,
M. Cantile, G. Botti, R. Tarallo, F. Rizzo, G. Nassa, A. Weisz
C17 BCL6 regulates triple-negative breast cancer stem cells by suppressing the Notch pathway repressor NUMB
F. De Santis (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy), T. Volpari S.L. Romero-Cordoba, S. Faraci,
O. Rondinone, F. Farris, L. Castagnoli, C. Puricelli, A. Koshorke, G. Fucà, R. Marullo, C. Tripodo, E. Tagliabue, L.
Cerchietti, F. De Braud, S.M. Pupa, M. Di Nicola
C19 HMGA1 pseudogenes as oncogenic competitive endogenous RNAs
M. De Martino (Istituto di Endocrinologia ed Oncologia Sperimentale del CNR, Naples Italy), A. Fusco, F. Esposito
C29 Defination of a genetic signature to predict platinum resistance in ovarian cancer
C. De Marco (Università “Magna Graecia”, Catanzaro Italy), A. Di Cello, S. Migliozzi, C. Mignogna, D. Malanga, F. Zullo,
G. Viglietto
F14 Lung cancer cells with hybrid phenotype possess the highest ability to initiate metastasis and negatively
modulate NK cells recruitment to metastatic site
F. Giovinazzo, C. Gardelli, G. Pollaci, P. Orecchia, M. Parodi, G. Centonze, L. Roz, M. Vitale, G. Sozzi, G. Bertolini
(Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy)
N12 Liquid biopsy as tool to monitor advanced non-small cell lung cancer (NSCLC) during systemic treatment
E. Zulato, L. Bonanno, I. Attili, A. Pavan, G. Nardo, P. Del Bianco, A. Boscolo Bragadin, M. Verza, L. Pasqualini,
G. Pasello, M. Fassan, M. Rugge, G.L. De Salvo, F. Calabrese, V. Guarneri, A. Amadori, P.F. Conte, S. Indraccolo (Istituto
Oncologico Veneto, IOV-IRCCS, Padova, Italy)
9Friday, November 8th
10.30-13.00 Poster Discussion 2B
NOVEL THERAPUTIC APPROACHES AND DRUG RESISTANCE Partenope Room
Chairs: Roberto Bianco, Naples (Italy) - Alfredo Budillon, Naples (Italy)
E5 MYC modulates breast cancer stem cell response to PARP inhibitors via SAM68 and RAD51
A. Turdo (University of Palemo, Italy), M. Gaggianesi, A. Chinnici, V. Veschi, D.S. Sardina, G. Ganduscio, F. Verona,
M. Buffa, S. Ficarella, N. Faldetta, G. Stassi, M. Todaro
E10 An in vitro preclinical approach to test drugs targeting chronic myeloid leukemia progenitor/stem cells
I. Tusa (Department of Experimental and Clinical Biomedical Sciences, University of Florence, Italy), G. Cheloni,
M. Poteti, A. Silvano, A. Tubita, A. Gozzini, P. Dello Sbarba, E. Rovida
E12 Acute myeloid leukemia cells dysregulate normal hematopoiesis by releasing extracellular vesicles
S. Trino (IRCCS Centro di Riferimento Oncologico della Basilicata (CROB), Rionero in Vulture, PZ, Italy), I. Laurenzana,
D. Lamorte, M. Santodirocco, L. Di Mauro, P. Musto, L. De Luca, A. Caivano
I21 A defective transcription coupled-nucleotide excision repair (TC-NER) as a possible cause of acquired
resistance to trabectedin in myxoid liposarcoma patient derived xenograft (PDX) models
I. Craparotta (Istituto di Ricerche Farmacologiche Mario Negri, Milan Italy), M. Mannarino, B.Ballabio, F. Frapolli,
B. Bello, P. Ponzo, M. Marchini M., M. D’ Incalci
L8 P21-activated kinases involvement in EGFR inhibitor resistant colorectal cancer
D. Esposito, A. Pesapane (University of Naples “Federico II”, Naples Italy), C. Di Mauro, S. Belli, F. Napolitano,
A. Santaniello, P. De Placido, P. Cascetta, A. Carratù E. Mozzillo, R. Marciano, A. Servetto, L. Formisano, R. Bianco
N8 Oncogenic role of the aminopeptidase ERAP1 in Hedgehog-dependent cancer
F. Bufalieri (University La Sapienza, Rome Italy), P. Infante, F. Bernardi, M. Caimano, M. Moretti, L. Lospinoso Severini,
A. Peschiaroli, S. Pazzaglia, G. Melino, F. Locatelli, O. Ayrault, D. Fruci, L. Di Marcotullio
P5 Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostgic factors for therapy
response and survival in high grade serous ovarian cancer
G. Benvenuto (University of Padova, Italy), P. Todeschini, L. Paracchini, E. Calura, R. Fruscio, C. Romani, L. Beltrame,
P. Martini, A. Ravaggi, L. Ceppi, G. Sales, F. Donati, P. Perego, L. Zanotti, S. Ballabio, T. Grassi, M. Delle Marchette,
G. Tognon, E. Sartori, M. Adorni, F. Odicino, M. D’Incalci, E. Bignotti, C. Romualdi, S. Marchini
U5 Inducing cancer indolence by targeting mitochondrial Complex I is potentiated by blocking macrophage-
mediated adaptive responses
I. Kurelac (University of Bologna, Italy), L. Iommarini, R. Vatrinet, L.B. Amato, B. Kofler, I. Malanchi, A.M. Porcelli,
G. Gasparre
12.00-13.00 Poster viewing with authors Mirabilis Room
13.00-14.00 Lunch
10Friday, November 8th
14.00-15.30 Tumor progression, microenvironment and metastases Plenary Room
Chairs: Stefania Scala, Naples (Italy) - Giulia Taraboletti, Bergamo (Italy)
Deconstructing the metastatic microenvironment
Ilaria Malanchi, London (UK)
U2 NASH-related experimental liver carcinogenesis is critically affected by Hypoxia-inducible factor 2
B. Foglia (University of Turin, Italy), S. Sutti, E. Morello, S. Cannito, C. Rosso, E. Novo, C. Bocca, M. Maggiora, V.
Foscaldi, G.M. Villano, S. Bruzzì, N.N. Ramavath, R. Younes, P. Pontisso, E. Bugianesi, E. Albano, M. Parola
Vascular malformations in cancer and other pathologies
Elisabetta Dejana, Milan (Italy)
U1 Multimerin-2 maintains vascular stability and permeability to control cancer cells dissemination
E. Poletto (National Cancer Institute Aviano (CRO), IRCCS, Aviano, Italy) R. Pellicani E. Andreuzzi, A. Fejza, A. Paulitti,
R. Colladel, G. Tarticchio, R. Doliana, P. Sabatelli, A. Colombatti, P. Bonaldo, M. Mongiat
15.30-16.15 Closing Lecture Plenary Room
The microbiota in cancer progression
Maria Rescigno, Milan (Italy)
16.15-16.45 Award Ceremony Plenary Room
“Piero Trivella” Awards for the best posters
“Guido Berlucchi Foundation” Awards for the best posters
“Guido Berlucchi Foundation” Award for the best oral presentation
16.45 Closing remarks
11Scientific Information
CME CREDITS
No. 5,1 Italian Ministry of Health for the following Professions and Disciplines: Medical Surgeon (Disciplines: Haematology, General (Fa-
mily Doctors) Medicine, Medical Genetics, Oncology, Pathological Anatomy, Pharmacology and Clinical Toxicology, Clinical Pathology,
Internal Medicine); Biologist, Pharmacist, Chemist (Discipline: Analytical Chemistry); Physicist (Discipline: Health Physics); Veterinary
Surgeon.
SLIDES
Slides must be in English. Computer videoprojection will be available in Power Point. Please communicate to the Organizing Secretariat
your different requirements as soon as possible. Slides have to be handed to the slide centre one hour before the session beginning.
PRIZES
Wednesday, November 6th
• “Elena Cappannini” award for the best 2018 publication
• “Pezcoller Foudation-SIC - Patrizia Coser” Fellowship 2020-2021
Friday, November 8th
• “Piero Trivella” Awards for the best posters
• “Guido Berlucchi Foundation” Awards for the best posters
• “Guido Berlucchi Foundation” Award for the best oral presentation
General Information
Dates: November 6th-8th, 2019
Congress Venue: Hotel Royal Continental - Via Partenope 38/44 - Naples
How to reach the Congress Venue
By plane: From Napoli Capodichino airport take the Alibus busline and get off at Piazza Municipio. Continue on foot to via Acton and
take bus 154; get off at the stop for Saint Lucia, and the hotel is just a few steps away.
By train: From Napoli Centrale railway station, take Metro Line 1 (Garibaldi, just outside the station), going towards Dante, and get off
at Toledo. From there, you can take a taxi or enjoy a pleasant walk along Via Toledo and through Piazza del Plebiscito.
By car: From the motorway, drive towards Piazza Municipio/Porto, continue on Via Acton, cross the Tunnel della Vittoria and follow Via
Morelli. After 100m turn left into Piazza Vittoria.
Turn left to stay in the square and then turn left into via Arcoleo. Just before the entrance to the Tunnel della Vittoria, turn right into via
Chiatamone. At number 54, turn right into via Dumas and at the end of the road turn left into the garage of the hotel.
SIC Secretariat
Società Italiana di Cancerologia
Via Giacomo Venezian, 1 - 20133 Milano MI
E-mail: sic@istitutotumori.mi.it - www.cancerologia.it
Organizing Secretariat
Adria Congrex s.r.l.
Via Sassonia, 30 - 47922 Rimini RN
E-mail: sic2019@adriacongrex.it - www.adriacongrex.it
OFFICIAL LANGUAGE
English. Simultaneous translation will not be provided.
12General Information
BADGE
Participants and exhibitors are kindly requested to wear their badge during the congress.
CERTIFICATE OF ATTENDANCE
Certificate of attendance is given to all registered participants at the end of the congress.
EXHIBITION AND SPONSORSHIP
A technical, pharmaceutical and publication exhibition will be held in the Congress Venue. For any information please contact the
Organizing Secretariat.
REGISTRATION FEES
Registration Fees On site Registration
SIC MEMBER (*) € 430,00
NON SIC MEMBER (**) € 530,00
SIC MEMBER UNDER 35 (*) € 280,00
NON SIC MEMBER UNDER 35 (**) € 350,00
(*)VAT non applicable as for law ex Art.4 DPR 633/72; (**) VAT included
The VAT rate will be applied depending on the Italian fiscal law at the time of payment.
Registration fees include:
• admission to the scientific sessions
• admission to the exhibition area
• name badge and congress kit
• welcome cocktail
• coffee breaks and light lunches
• abstracts book
• attendance certificate
• CME certificate
• social dinner
Payment Methods and Details
Payment on site: by cash or credit card (accepted VISA and MASTERCARD)
Cancellation
In case of cancellation no reimbursement is foreseen.
13Thanks to 14
105
SIC Secretariat
Società Italiana di Cancerologia
Via G. Venezian, 1
20133 Milano MI
E-mail: sic@istitutotumori.mi.it
www.cancerologia.it
Organizing Secretariat
Via Sassonia, 30
47922 Rimini RN
E-mail: sic2019@adriacongrex.it
www.adriacongrex.itPuoi anche leggere
